Respiratory Syncytial Virus (RSV) Vaccine

    Not Recruiting
  • sponsor
    Janssen Vaccines & Prevention B.V.
Updated on 10 August 2022


The study will enroll up to 23,000 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRTD) when compared to placebo in adults aged 60 years and above.


  • Condition: Vaccine
  • Drug: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF. Other Name: JNJ-64400141
  • Clinical Trial Identifier: NCT04908683
  • Sponsor: Janssen Vaccines & Prevention B.V.

Condition Respiratory Syncytial Virus, vaccine, Respiratory Syncytial Virus (RSV), Vaccines, rsv
Clinical Study IdentifierTX285146
SponsorJanssen Vaccines & Prevention B.V.
Last Modified on10 August 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note